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Abstract: The process of viral integration into the host genome is an essential step of the HIV-1 life
cycle. The viral integrase (IN) enzyme catalyzes integration. IN is an ideal therapeutic enzyme
targeted by several drugs; raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG), and bictegravir
(BIC) having been approved by the USA Food and Drug Administration (FDA). Due to high HIV-1
diversity, it is not well understood how specific naturally occurring polymorphisms (NOPs) in
IN may affect the structure/function and binding affinity of integrase strand transfer inhibitors
(INSTIs). We applied computational methods of molecular modelling and docking to analyze the
effect of NOPs on the full-length IN structure and INSTI binding. We identified 13 NOPs within the
Cameroonian-derived CRF02_AG IN sequences and further identified 17 NOPs within HIV-1C South
African sequences. The NOPs in the IN structures did not show any differences in INSTI binding
affinity. However, linear regression analysis revealed a positive correlation between the Ki and EC50
values for DTG and BIC as strong inhibitors of HIV-1 IN subtypes. All INSTIs are clinically effective
against diverse HIV-1 strains from INSTI treatment-naïve populations. This study supports the use
of second-generation INSTIs such as DTG and BIC as part of first-line combination antiretroviral
therapy (cART) regimens, due to a stronger genetic barrier to the emergence of drug resistance.
Keywords: integrase; naturally occurring polymorphisms; HIV-1; molecular modelling; molecular
docking; diversity
1. Introduction
The HIV/AIDS pandemic continues to be a significant problem worldwide [1]. The viral integration
process, which is the insertion of viral DNA into host genomic DNA, is an indispensable step of the
retroviral life cycle and is catalyzed by the viral integrase (IN) enzyme [2]. Integration is achieved
via two distinct sequential catalytic activities, 3′ processing and strand transfer. IN first processes
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viral DNA by excising a dinucleotide at the 3′ end, exposing hydroxyl ends. IN then catalyzes the
introduction of the prepared DNA into genomic DNA by facilitating a nucleophilic attack upon genomic
DNA [3,4]. The same active site in IN, which contains a retroviral highly conserved DDE motif and
magnesium ions, performs both activities [5,6]. HIV-1 IN is a 32 kDa protein that functions as a tetramer
or multimer [3,4]. A monomer consists of three distinct domains; the N-terminal domain (NTD)
comprising residues 1–46, the catalytic core domain (CCD) comprising residues 56–186 within which
the active site DDE motif (aspartate (D64), aspartate (D116), and glutamate (E152) is present, and the
C-terminal domain (CTD) comprising residues 195–288 [7,8]. Several integrase strand transfer inhibitors
(INSTIs) have been developed to target HIV-1 IN to prevent viral integration into the host genome.
The four INSTIs available thus far include raltegravir (RAL) and elvitegravir (EVG) that are considered
as first-generation inhibitors, while dolutegravir (DTG) and bictegravir (BIC), along with the late-phase
clinically trialed cabotegravir (CBT), are classified as second-generation INSTIs [9]. At present, first-line
combination antiretroviral therapy (cART) regimens for HIV-1 are expected to include the INSTI
DTG according to World Health Organization (WHO) recommendations [10], as it has been shown to
possess a higher genetic barrier to drug resistance development as compared with RAL and EVG [11].
HIV-1 is a genetically highly diverse virus, forming different subtypes, recombinant and region-specific
variants [12]. Development of INSTIs, as with most pharmaceutical agents, was primarily conducted by
companies in First World nations, where subtype B is the most predominant variant or subtype [13,14].
It remains unclear what effects naturally occurring polymorphisms (NOPs) may have upon the IN
structure and INSTI susceptibility. This lack of data poses a challenge in concluding the effects of NOPs
on the binding of INSTIs to HIV-1 IN subtypes [15–19].
In this study, computational methods, which include molecular modelling and docking, were used
to determine if NOPs affect INSTI binding to HIV-1 IN subtype C (HIV-1C) and a circulating recombinant
form of HIV-1 IN CRF_02_AG. The recently resolved cryogenic electron microscopy full-length HIV-1
subtype B IN structure allowed us to build accurate and complete tetrameric three-dimensional
structures of HIV-1C IN and of HIV-1 IN CRF_02_AG. The value of having accurate protein models
allows us to infer the exact mode of interactions formed between active site residues of HIV-1 subtypes
and drug atoms. HIV-1 subtype C derived from a South African cohort was chosen as one of our
IN models, as it represents the most prevalent subtype both globally and for sub-Saharan Africa in
particular [14,19,20]. Our focus on a Cameroonian cohort was spurred on by the previously reported
HIV-1 diversity present in Cameroon with all known subtypes/variants found within Cameroon [21,22].
Furthermore, the full-length Cryo-EM HIV-1 IN structure, which was used as the template in our
molecular modelling, served additionally as a subtype B IN model in our study, the predominant strain
in developed nations.
2. Materials and Methods
2.1. Ethics Statement
The study used sequences from two African settings: South Africa and Cameroon.
Ethical permission for this study was obtained from the Health Research Ethics Committee of
Stellenbosch University (N14/10/130—approved on 13 August 2019 and N15/08/071—approved on 26
March 2019). Ethics protocols are revised and renewed each year. The study was conducted according
to the ethical guidelines and principles of the international Declaration of Helsinki 2013, South African
Guidelines for Good Clinical Practice, and the Medical Research Council (MRC) Ethical Guidelines for
Research. A waiver of consent was awarded to conduct sequence analyses.
2.2. Study Design
HIV-1-positive plasma samples were obtained from the Centre for the Study and Control of
Communicable Diseases (CSCCD), University of Yaoundé I, Cameroon (n = 37), and South Africa
samples (n = 91) were requested, with permission, through the National Health Laboratory Services
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(NHLS) within the Division of Medical Virology, Stellenbosch University, South Africa. Samples were
collected between March 2017 and February 2018 [23]. We excluded patient samples with no previous
cART history and patients receiving first-line cART. Patients had their samples sent to the NHLS for
HIV-1 genotypic resistance testing. Treatment failure is defined according to the South Africa adult
antiretroviral guidelines by a confirmed viral load of >1000 copies/mL on two measurements taken
two to three months apart.
2.3. Nucleic Acid Extraction
HIV-1 RNA extraction was performed using the QIAamp Viral RNA Mini Extraction Kit’s Spin
protocol, according to the manufacturer’s instructions (Qiagen, Hilden, Germany). Briefly, 140 µL of
plasma was used as a starting volume. A larger starting volume of 280 µL of plasma was used for
samples with very low viral titers. Viral RNA was stored at −80◦C until use.
2.4. PCR Amplification and Sequencing
The synthesis of complementary DNA (cDNA) and first-round PCR amplification were performed
using the Invitrogen SuperScript® III Reverse Transcriptase (RT) reagents (Invitrogen, Karlsruhe,
Germany), as per the manufacturer’s instructions. In-house amplification of the IN region (867 bp,
positions 4230–5096, HXB2 strain) by nested RT-PCR was performed as previously described by our
laboratory [24,25]. Purified amplicons were sequenced on both strands with conventional Sanger
DNA sequencing, using the ABI Prism Big Dye® Terminator sequencing kit version 3.1 and run
on the ABI 3130xl automated DNA sequencer (Applied Biosystems, Foster City, California, USA),
according to manufactures instructions. Primers spanning the full-length integrase (867 bp) were used
to sequence the PCR products in both directions. These included sequencing primers Poli6 and Poli7,
and additional sequencing primers were used, namely Poli2 (TAAARACARYAGTACWAATGGCA),
relative to position 4745–4766, and KLVO83 (GAATACTGCCATTTGTACTGCTG), corresponding to
position 4750–4772.
2.5. Consensus Sequence Alignment and Mutation Detection
We performed a search on the HIV Los Alamos National Library (LANL) database (https:
//www.hiv.lanl.gov/components/sequence/HIVsearch.com). Our search inclusion criteria included
all Cameroonian HIV-1 subtype CRF02_AG IN sequences identified from treatment-naïve patients.
We selected one sequence per patient, and all problematic sequences were excluded from further
analyses. The consensus sequence representing CRF02_AG was generated using the CRF02_AG
study sequences (n = 37) as previously reported [25], accession number: MN816445-MN816488,
while the consensus sequence for subtype C was derived from cohort sequences (n = 91,) as previously
reported [26]. Nucleotide sequences were verified for stop codons, insertion, and deletions using an
online quality control program on the HIVLANL database (https://www.hiv.lanl.gov/content/sequence/
QC/index.htm). Multiple sequence alignments were done with MAFFT version 7, from which the
consensus sequence was derived [27]. As part of quality control, each of the viral sequences were
inferred on a phylogenetic tree in order to eliminate possible contamination. The amino acid sequence
alignment was extensively screened for the presence of primary and secondary resistance-associated
mutations (RAMs) and NOPs associated with resistance to known INSTIs.
2.6. Protein Modelling
A three-dimensional model was constructed for HIV-1C IN and recombinant form CRF02_AG
using Schrodinger Prime modelling software [28,29]. A suitable homologous template was identified
by performing a Blastp search using the consensus amino acid sequences of HIV1C IN and recombinant
form CRF02_AG. Prior to modelling, missing residues were fixed by re-modelling the structure of
template 5U1C using Schrodinger PRIME modelling software [30]. The Cryo-EM-solved IN subtype
B intasome structure (ID: 5U1C) was used as the homologous template for comparative modelling,
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as it shared a high sequence identity and coverage with HIV-1C IN from a South African cohort and
with the recombinant form CRF02_AG from a Cameroonian cohort. Additionally, as 5U1C contains a
mutation at residue 152, this was mutated back into glutamic acid during re-modelling.
2.7. Protein Preparation
Processing of protein models was performed using Schrodinger Protein Preparation Wizard,
which added hydrogen atoms, created disulphide bonds, assigned bond orders, filled in any missing
side chains, and optimized the H-Bonds [31]. Magnesium ions were extracted from the prototype
foamy virus and simian immunodeficiency virus IN experimental structures.
2.8. Model Validation
To assess the quality of the constructed IN protein models, a variety of structural parameters
were tested within each model. The Structural Analysis and Verification Server (SAVES) was used
for this purpose and includes the tools Procheck, Whatcheck, Prove, Verify3D, and ERRAT [32–36].
The cut-off values used by the tools were as follows: >80% for Verify3D, <1% for Prove, >50 for ERRAT.
Whatcheck and Procheck are further subdivided into tests, but both make use of a Ramachrandran
plot analysis, which is deemed passed if the majority of residues are within the allowable region.
Furthermore, the root mean square deviation (RMSD) analysis was conducted using PYMOL/Maestro
molecular visualizing software to compare backbone structural similarity to the experimentally solved
5U1C template structure [37].
2.9. INSTI Extractions and Molecular Docking
The INSTI’s RAL, EVG, DTG, and BIC were extracted from known solved structures deposited
inside the Protein Data Bank (PDB) with the respective identifiers 3oya, 3l2u, 3s3m, and 6rwm [38–41].
The structures were superimposed upon our generated IN models using PYMOL and subsequently
saved as protein–ligand complexes.
The INSTI CBT has not been published in complex with an IN protein, therefore molecular docking
was done to predict the binding mode, affinity, and chemical interactions. Docking was performed
using SMINA, a fork of AUTODOCK VINA [42,43]. The three-dimensional (3D) structures for CBT
were acquired from the ZINC database [44]. Conversion of receptor and ligand structures from the
respective pdb and sdf formats to pdbqt was done using OBABEL [45]. The docking grid was centered
on the active site with a box size of 20Å in all planes. CBT was docked to each subtype structural
intasome HIV-1C, B and AG, respectively. Ranking of generated binding poses was done based on
the binding affinity values calculated using the Vinardo Scoring function with the top binding pose
complex selected for the next step [46].
2.10. Refinement and Energy Minimisation
The refinement process involved repeating the aforementioned protein preparation steps.
The complexes were subsequently energy-minimized using the CHARMM-GUI webserver [47]
for structural preparation and energy minimization using default CHARMM-GUI-generated parameter
files. The molecular dynamics engine software utilized was GROMACS 2018.1 [48] and charmm36M
forcefield [49].
2.11. Binding Affinity Calculation and Interaction Analysis
The energy-minimized structures were desolvated and the ions removed using PYMOL.
The complexes were separated into two separate files, one for IN as the receptor(s) and one for
the INSTIs as the ligand(s). To calculate the binding affinity, the score only function was used
within SMINA in combination with the Vinardo scoring function. Pymol was used to calculate polar
interactions formed between the IN protein, DNA, MG, and the drugs.
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2.12. Binding Site Analysis
The spatial and chemical features of the active sites containing the DDE motif of each IN subtype
were compared to one another using PYMOL/MAESTRO. Briefly, the residues encompassing the
binding site were determined by aligning each IN-INSTI complex to one another and extracting
all residues within a 5Å radius of the inhibitor binding site. The binding sites were superimposed
to determine the difference by measuring the Root Mean Square Deviation (RMSD) values for the
backbone atoms of the protein chains.
3. Results
3.1. Sequence Alignments and Protein Structure Assessment
Two IN consensus protein sequences, corresponding to the South African and Cameroonian
cohorts respectively, were aligned to the sequence of the subtype B IN structure (ID:5u1c) (Figure 1).
The sequence identity was calculated to be 98% for both sequences when compared with subtype B.
The alignment revealed 13 NOPs within the Cameroonian cohort-derived CRF02_AG IN sequences.
The identified polymorphisms being K14R, V31I, V72I, L101I, T112V, T124A, T125A, K136T, I151V,
V201I, T206S, V234I, S283G. The alignment also showed 17 NOPs within a South African cohort-derived
Subtype C consensus sequence, namely D25E, V31I, M50I, V72I, F100Y, L101I, T112V, T124A, T125A,
K136Q, I151V, V201I, T218I, V234I, R269K, D278A, S283G (Supplementary Figure S1). The constructed
IN models were validated with the following scores obtained with the SAVES server tests. CRF02_AG
IN: Verify3D, 71%; ERRAT, 93/100; Prove, 7.8%; and for the Ramachandran plot analysis, 86.1% of
residues are within the most favored region. Subtype C IN: Verify3D, 74%; ERRAT, 92/100; Prove,
7.8%; and for the Ramachandran plot analysis, 86.1% of residues are within the most favored region.
Subtype B IN: Verify3D, 71%; ERRAT, 92/100; Prove, 10.3%; and for the Ramachandran plot analysis,
82.6% of residues are within most favored region.
Figure 1. Amino acid sequence alignment of integrase variants subtype B, subtype Cza, and CRF_02_AG,
respectively. Red highlighted residues indicate polymorphism locations in comparison with the Subtype
B template. Blue highlighted residues indicate the aspartate (D64), aspartate (D116) and glutamate
(E152) DDE motif.
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The RMSD analysis score was found to be approximately 0.4Å when all three structures were
compared to one another. In addition, there was minimal difference in secondary structural makeup
(Figure 2). However, reference subtype B structure forms an extra helical turn absent in Subtype C
and CRF02_AG.
Figure 2. (a) A superimposition of all three integrase models showing high backbone identity and
secondary structure conservation. (b) CRF02_AG integrase (IN) model colored according to secondary
structure and in cartoon depiction. (c) Subtype B IN model colored according to secondary structure
and in cartoon depiction. (d) Subtype C IN model colored according to secondary structure and in
cartoon depiction. Encircled in red is the secondary structure difference observed between the template
structure and the generated IN models. Light blue indicates the helices, purple indicates beta-sheets,
and tint color indicates loops.
3.2. Molecular Docking and Interaction Analysis
The molecular docking methodology was validated using the genetics algorithm (AutoDock),
providing a correlation of the experimental data (half-maximal effective concentration, EC50) with
the binding affinities showing reliable statistics (Supplementary Tables S1 and S2, Figure 3) [50].
Subsequently, rescoring/docking assays was done using VINA of the five FDA approved and late-phase
clinical trial INSTI’s showed minimal differences in binding affinity between one another, with less
than 2 kcal/mol difference observed. The obtained binding affinities furthermore were comparable
when SMINA was used to rescore Prototype Foamy Virus (PFV)-INSTI or Simian Immunodeficiency
(SIV)-INSTI complexes. (Table 1). In Table 2, most of the drugs made two ionic interactions with
Magnesium ions, except for EVG and BIC in HIV-1B IN due to the different orientation of the active
site as a result of remodelling missing residues.
Viruses 2020, 12, 936 7 of 12
Figure 3. Linear relationship between the predicted binding constants calculated from the docking
studies of integrase strand transfer inhibitors (INSTI) with HIV Ins and the experimental half-maximal
effective concentration (EC50) values determined from the TZM-bl cells-based assay.
Table 1. Vinardo binding affinity scores predicted for each INSTI bound to the three IN subtypes








Raltegravir −7.2 −4.4 −5.1 −6.1
Elvitegravir −3.7 −3.4 −3.4 −4.0
Dolutegravir −3.0 −3.4 −3.0 −5.4
Bictegravir −4.0 −3.5 −3.5 −3.9
Cabotagravir −6.5 −5.7 −7.0 N/A
Table 2. Summary of all interactions observed between the five INSTIs and three IN subtypes. Listed
also are interactions which occur between INSTI and PFV/SIV nucleic acid.
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Table 2. Cont.
































































Number outside bracket indicates total number of interactions. Supplementary Figures S2–S6. RAL, raltegravir;
DTG, dolutegravir; EVG, elvitegravir; BIC, bictegravir; CBT, cabotegravir.
3.3. Binding Site Analysis
We calculated differences in total surface area, with 860Å2 for subtype B IN, 969Å2 for subtype C
IN, and 1041Å2 for CRF_02_AG IN. RMSD analysis show that subtypes C IN and CRF_02_AG deviate
by 0.309Å and 0.44Å, respectively. The NOP I151V was found to occur within the binding site, but
does not directly interact with INSTI’s. NOP I151V is present in both subtype C and CRF_02_AG IN’s.
4. Discussion
The NOPs that have been identified in subtype C and CRF_02_AG IN have not been previously
associated with HIV-1 IN drug resistance, except for the polymorphism M50I. M50I was identified in
our subtype C IN sequences and this polymorphism has been reported to reduce DTG susceptibility
when found in combination with the mutation R263K in HIV-1 subtype B IN [51,52]. However, in our
study, the mutation R263K was not present. Furthermore, M50I is not able to cause drug resistance
on its own but increases the effect of resistance exhibited by R263K [51]. In our study, M50I had no
effect on INSTI’s binding to IN. NOPs were found to be occurring within their natural prevalence rates
and these NOPs have minimal effect on INSTI susceptibility when occurring alone, such as in the case
of M50I [51]. This is in contrast to the study by Brado et al. that reported an impact of NOPs on the
stability of the protein complex, suggesting they may contribute to an overall potency against INSTIs.
Our study is, however, in agreement with a study by Chitongo et al., 2020 that showed that one known
major resistance mutation, G140S, had an effect on DTG drug binding in HIV-1C IN in combination
with NOP’s. Therefore, NOPs alone have a negligible effect on drug binding [53].
A comparison of the backbone structures of the modelled IN proteins showed high structural
similarity with one another with RMSD values less than 0.4Å, suggesting similar fold between the
protein structures. Our IN homology modelling showed one slight secondary structural feature
alteration within the N-terminal domain. Subtype B displayed a helical turn absent in Subtype C and
CRF02_AG IN. Secondary structural features, such as helices, may influence the accessibility of drugs
to a protein’s active site, either by directly changing the binding pocket properties or through affecting
stability of the whole protein [54]. In our study, the structural alteration had no effect on drug binding
as it is located further away from the active site.
Extractions showed that all INSTIs are able to bind to either of the tested IN subtype structures with
plausible binding poses, which is in agreement to the previously reported PFV or SIV binding poses.
No significantly reduced binding affinity was observed for each of the INSTIs, implying no negative
alteration to the binding site which may prevent INSTI drug binding. Differences in binding affinity are
present. The Binding affinity is an indication of how strong the ligand is binding to the active site. NOPs
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associated with a reduction to EVG susceptibility have been previously reported to occur with a relatively
high frequency within CRF02_AG IN, however those NOPs were not identified in our study [55–57].
Magnesium ions are responsible and important for the binding of DNA. INSTIs competitively
inhibit this process by binding to the magnesium ions [58–60]. It was therefore expected that interaction
analysis would reveal that an interaction(s) takes place between the INSTIs and magnesium ions
present within IN active sites. The interaction(s) with magnesium ions are considered to be essential
for inhibition to take place, whereas other interactions are considered nonessential for the activity of
INSTIs to take place. Therefore, we considered an INSTI to be successfully bound if interaction analysis
predicted interactions occurring with magnesium ions. It may, however, be plausible that NOPs favor
or reduce the likelihood of additional interactions occurring and thereby enhancing binding affinity.
In our study, all drugs make contact with MG ions but only 1MG contact is found for HIV-1B IN bound
to EVG and BIC. The remodeling of missing residues could be a reason for HIV-1B not making two
MG ion contacts with EVG and BIC, but this is a surprising finding that warrants further investigation.
Binding site analysis further supports the results from the rescoring/molecular docking assay.
The analyses conducted show that binding sites between each IN structure are identical. One NOP
I151V is present within the binding sites of our study, but does not induce any effect beyond a slight
spatial change due to its different side chain orientation.
The free energy of binding values calculated between the different proteins and drugs using
the Molecular Mechanics Poisson-Boltzmann Surface (MM-PBSA) package confirmed no significant
difference in the strength of binding between the drugs and different HIV-1 IN protein subtypes.
However, the inhibition constant (Ki) values and inhibitor potency EC50 values provided evidence
for DTG and BIC as strong binders with high inhibition values, suggesting DTG and BIC as good
candidates for treatment of the three caused by the three different HIV-1 subtypes.
Future work should include viral integration assays to determine if DTG, BIC, and CBT can
prevent viral integration within plasmids containing different HIV IN subtype sequences.
5. Conclusions
Our study showed that unique polymorphisms within geographically distinct HIV-1-infected
populations with different variants do not prevent INSTI binding. However, linear correlation between
the inhibition constant (Ki) values derived from docking experiments and experimental EC50 values
for INSTI’s suggest DTG and BIC as strong inhibitors. We therefore put forward that second-generation
DTG and BIC should be added to antiviral regimens as part of first-line regimens for HIV-1C IN
subtype infections, this would account for cross-resistance which may occur between EVG and RAL as
DTG and BIC may have a higher genetic barrier to resistance.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/12/9/936/s1,
Table S1: Binding affinities (∆G in kcal/mol), Table S2: Inhibition constants (Ki in µM) [61], Figure S1: HIV-1C and
CRF02_AG integrase mutation profiling, Figure S2: Interaction diagram showing different polar contacts being
formed between RAL and different IN subtypes, Figure S3: Interaction diagram showing different polar contacts
being formed between EVG and different IN subtypes, Figure S4: Interaction diagram showing different polar
contacts being formed between DTG and different IN subtypes, Figure S5: Interaction diagram showing different
polar contacts being formed between BIC and different IN subtypes, Figure S6: Interaction diagram showing
different polar contacts being formed between CBT and different IN subtypes.
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